Figure 1From: Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia Enrolment into NEXT and VENICE as of 31 September 2013. Back to article page